Because of the growing availability and feasibility of genetic testing, neurodevelopmental disorders of identified genetic etiology (i.e., genetic disorders) are increasingly diagnosed in early childhood, perinatally or even prenatally. Multiple genetic disorders are also associated with high risk for a diverse range of childhood psychopathological outcomes, such as attention‐deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Genetic disorders therefore offer an appealing opportunity: mapping between genetic differences, atypical brain function, cognitive development, and risk for psychopathological outcomes. Here we focus on a specific monogenic disorder, fragile X syndrome (FXS), to illustrate the complexities of mapping efforts across levels of description, and the need for a developmental perspective throughout. In applied terms, the comparison between FXS and other genetic disorders at high risk also pinpoints subtly diverging profiles of risk and thus the need for information about differences in early neurocognitive trajectories, to optimize early intervention in a syndrome‐specific way. Understanding neurodevelopmental trajectories to both poor and good outcomes across multiple genetic disorders will require increasing collaborations between basic and clinical neuroscientists, with mechanisms of typical and atypical neurocognitive development clearly in focus.